Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 11/20 | 0.39 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19951733 | 0.86 | RIPK1 (0.36) | RIPK1BDKRB1TRPV1OPRL1KDM4E | |
| SCHEMBL19948761 | 0.81 | PDE10A (0.41) | ALDH1A1LMNAKDM4E | |
| SCHEMBL17040899 | 0.79 | BDKRB1 (0.44) | BDKRB1 | |
| SCHEMBL19970246 | 0.73 | — | — | |
| SCHEMBL326748 | 0.71 | CYP11B1 (0.38) | — | |
| SCHEMBL23362327 | 0.70 | CA12 (0.44) | BDKRB1TRPV1 | |
| SCHEMBL23361981 | 0.70 | WDR5 (0.42) | TRPV1 | |
| SCHEMBL19948657 | 0.70 | CYP11B1 (0.43) | — | |
| SCHEMBL19948929 | 0.69 | BDKRB1 (0.33) | BDKRB1 | |
| SCHEMBL23362492 | 0.69 | CA1 (0.44) | BDKRB1ALDH1A1LMNATRPV1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2018-03-15 | — | — | US | disclosed |
| WO-2018049152-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | RIPK1 463/4885BDKRB1 639/4885ALDH1A1 1681/4885 |
| US-20180072741-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | RIPK1 465/4885BDKRB1 712/4885ALDH1A1 2137/4885 |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, MAPKAPK5 | RIPK1 463/4885BDKRB1 639/4885ALDH1A1 1681/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | RIPK1 465/4885BDKRB1 712/4885ALDH1A1 2137/4885 |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | RIPK1 465/4885BDKRB1 712/4885ALDH1A1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.